--- title: "Aligos Therapeutics | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 2.83 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/285609301.md" datetime: "2026-05-07T20:14:08.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285609301.md) - [en](https://longbridge.com/en/news/285609301.md) - [zh-HK](https://longbridge.com/zh-HK/news/285609301.md) --- # Aligos Therapeutics | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 2.83 M Revenue: As of FY2026 Q1, the actual value is USD 2.83 M, beating the estimate of USD 333.33 K. EPS: As of FY2026 Q1, the actual value is USD -2.21, beating the estimate of USD -2.25. #### Financial Performance for the Three Months Ended March 31, 2026 - **Revenue from customers**: Aligos Therapeutics, Inc. reported $2,830 thousand in revenue for the three months ended March 31, 2026, compared to $311 thousand for the same period in 2025. - **Net Loss**: The company reported a net loss of - $23,040 thousand for the three months ended March 31, 2026, which is a decrease from a net income of $43,088 thousand for the same period in 2025. - **Research and Development (R&D) Expenses**: R&D expenses increased to $23,352 thousand in Q1 2026 from $14,502 thousand in Q1 2025, primarily due to increased third-party expenses for the pevifoscorvir sodium Phase 2 clinical trial. R&D stock-based compensation was $700 thousand in Q1 2026, up from $500 thousand in Q1 2025. - **General and Administrative (G&A) Expenses**: G&A expenses were $6,407 thousand in Q1 2026, compared to $5,052 thousand in Q1 2025. The decrease in G&A for the comparative period was primarily due to a decrease in legal and other related expenses. G&A stock-based compensation was $600 thousand in Q1 2026, up from $400 thousand in Q1 2025. - **Interest and Other Income, Net**: The company recorded $811 thousand in net interest and other income for Q1 2026, a slight decrease from $880 thousand in Q1 2025. - **Change in Fair Value of Warrants**: Income from the change in fair value of 2023 common warrants was $3,395 thousand in Q1 2026, significantly lower than the $61,494 thousand recorded in Q1 2025. - **Total Operating Expenses**: Total operating expenses were $29,759 thousand in Q1 2026, up from $19,554 thousand in Q1 2025. - **Loss from Operations**: Loss from operations was - $26,929 thousand in Q1 2026, compared to - $19,243 thousand in Q1 2025. - **Income Tax Provision**: The income tax provision was - $317 thousand in Q1 2026, compared to - $43 thousand in Q1 2025. #### Balance Sheet Highlights - **Cash, Cash Equivalents, and Investments**: As of March 31, 2026, cash, cash equivalents, and investments totaled $54.9 million, down from $77.8 million as of December 31, 2025. Specifically, cash and cash equivalents were $29,980 thousand, and short-term investments were $24,929 thousand as of March 31, 2026. - **Total Assets**: Total assets were $64,558 thousand as of March 31, 2026, compared to $88,533 thousand as of December 31, 2025. - **Total Liabilities**: Total liabilities were $32,769 thousand as of March 31, 2026, down from $34,988 thousand as of December 31, 2025. - **Total Stockholders’ Equity**: Total stockholders’ equity was $31,789 thousand as of March 31, 2026, compared to $53,545 thousand as of December 31, 2025. #### Operational Metrics and Business Progress - **Pevifoscorvir sodium**: This drug candidate received Fast Track Designation from the U.S. FDA for chronic HBV infection. The Phase 2 B-SUPREME study is ongoing, with 74 participants enrolled in the HBeAg- cohort (Part 2a) and 103 in the HBeAg+ cohort (Part 1a) as of April 2026. A first interim analysis for the HBeAg- cohort indicated that futility criteria were not met, and the DSMB recommended increasing the sample size of Part 2a from 74 to 100 participants. - **Partnership**: Aligos Therapeutics, Inc. entered into an exclusive license deal with Xiamen Amoytop Biotech Co., Ltd. (Amoytop) for pevifoscorvir sodium in Greater China, including a $25 million upfront payment and up to $420 million in potential milestones plus royalties. - **ALG-170675**: This antisense oligonucleotide (ASO) for chronic HBV infection has begun IND-enabling studies, with Amoytop funding development costs in China. - **ALG-055009**: Evaluation of funding options, including potential out-licensing, is ongoing for this THR-β agonist for obesity and MASH. #### Outlook / Guidance Aligos Therapeutics, Inc. expects its cash, cash equivalents, and investments to provide sufficient funding for planned operations into the fourth quarter of 2026, including the anticipated $25 million upfront payment from the Amoytop deal. A second interim analysis for the HBeAg+ cohort of the B-SUPREME study is anticipated in the second half of 2026, with topline data for both HBeAg- and HBeAg+ cohorts expected in 2027. ### Related Stocks - [ALGS.US](https://longbridge.com/en/quote/ALGS.US.md) ## Related News & Research - [Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026 | ALGS Stock News](https://longbridge.com/en/news/286205055.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Yext to Announce First Quarter Fiscal Year 2027 Financial Results on June 2, 2026 | YEXT Stock News](https://longbridge.com/en/news/286970613.md) - [LOWE'S REPORTS FIRST QUARTER 2026 SALES AND EARNINGS RESULTS | LOW Stock News](https://longbridge.com/en/news/287043063.md) - [OS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026 | OSTX Stock News](https://longbridge.com/en/news/286607728.md)